Amneal Pharmaceuticals (AMRX) Total Non-Current Liabilities (2017 - 2026)

Amneal Pharmaceuticals' Total Non-Current Liabilities history runs 10 years deep, the most recent figure standing at $2.8 billion for Q1 2026.

• In Q1 2026, Total Non-Current Liabilities rose 18.03% year-over-year to $2.8 billion; the TTM figure through Mar 2026 stood at $2.8 billion (up 18.03% YoY), while the FY2025 annual figure was $2.8 billion, up 15.5% from the prior year.
• Total Non-Current Liabilities was $2.8 billion for Q1 2026 at Amneal Pharmaceuticals, down from $2.8 billion in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $2.9 billion in Q1 2022 to a low of $2.3 billion in Q1 2025.
• Historically, Total Non-Current Liabilities has averaged $2.7 billion across 5 years, with a median of $2.7 billion in 2023.
• The sharpest annual moves came in 2024 and 2026: Total Non-Current Liabilities slipped 12.44% in 2024, then advanced 18.03% in 2026.
• A 5-year view of Total Non-Current Liabilities shows it stood at $2.8 billion in 2022, then retreated by 9.62% to $2.6 billion in 2023, then declined by 5.79% to $2.4 billion in 2024, then advanced by 15.5% to $2.8 billion in 2025, then dropped by 0.66% to $2.8 billion in 2026.
• The last three Total Non-Current Liabilities figures came in at $2.8 billion (Q1 2026), $2.8 billion (Q4 2025), and $2.8 billion (Q3 2025), per Business Quant data.